key: cord-0898963-kepbdxnc
authors: Erdem Sumbul, Hilmi; Koc, Ayse Selcan; Pınar, Arzu; Zubeyir Aslan, Muhammed; Gulumsek, Erdinc; Koca, Hasan; Bulut, Yurdaer; Karakoc, Emre; Turunc, Tuba; Bayrak, Edip; Ozturk, Huseyin Ali; Avci, Akkan; Unal, Ilker; Kemal Icen, Yahya; Koc, Mevlut; Riza Sahin, Ahmet; Azim Okyay, Ramazan
title: Modified lung ultrasound score in evaluating the severity of COVID-19 pneumonia
date: 2021-04-30
journal: Ultrasound Med Biol
DOI: 10.1016/j.ultrasmedbio.2021.04.023
sha: 135ba856a3a56f63723a842e6b647467cad3cb5a
doc_id: 898963
cord_uid: kepbdxnc

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which is declared as a pandemic by the World Health Organization (WHO). In this study we aimed to determine the severity of pneumonia and the clinical parameters related to modified lung ultrasound score (mLUS) in patients with Covid-19 pneumonia. The study included 44 patients with proven Covid-19 pneumonia. Patients were divided into 3 groups as mild-moderate pneumonia (Group-I), severe pneumonia (Group-II) and critically-ill patients (Group-III) according to pneumonia severity. It was determined that mLUS values in Group I-II-III were 6.51 ± 4.12, 23.5 ± 5.9, 24.7 ± 3.9, respectively. mLUS values were significantly higher in Group-II and Group-III patients than in Group-I patients. There was a positive relationship between mLUS and age and NT-proBNP level and a negative relationship with PaO2 / FiO2. (p=0.032 and β=0.275 vs p=0.012 and β=0.315 vs p=0.001 and β= – 0.520, respectively).In patients with COVID-19 pneumonia, mLUS increases significantly with the severity of the disease.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 , which is declared as a pandemic by the World Health Organization (WHO). According to the WHO report, 80% of the cases who have the disease have mild symptoms. Pneumonia occurs in 14% of patients and pneumonia progresses in 6% of patients, causing serious illness (Liu et al. 2020; Mattiuzzi et al.2020) .

Pneumonia can progress to acute respiratory distress syndrome (ARDS), multi-organ dysfunction and death (Liu et al. 2020) . Many demographic, clinical, laboratory and imaging method data related to disease severity were determined. These can be summarized as advanced age, history of cardiovascular disease or risk factors, increased high sensitive cardiac troponin I (hs-cTnI), D-dimer, N-terminal pro-brain natriuretic peptide (NT-proBNP) , high sensitive C reactive protein (hs-CRP) and inflammatory cytokine levels, decreased lymphocyte level, hypoxia, hypotension, vasopressor requirement, low peripheral oxygen saturation (SpO2) and thorax computed tomography (CT) findings (Liu et al. 2020; Monastesse et al. 2017; Lyu et al. 2020; Bhatraju et al. 2020; Du et al. 2020) .

Lung ultrasound (Lung-US) is an examination that can be performed at the bedside in patients with Covid-19 pneumonia and can give us information about the severity of pneumonia. There are a few articles in the literature regarding the evaluation of Lung-US in patients with COVID-19 pneumonia, many of which are writings that share experience and images of their cases or suggest a review (Musolino et al. 2020; Mongodi et al. 2020; Vetrugno et al. 2020; Peng et al. 2020; Sofia et al. 2020; Poggiali et al. 2020) . We use the Lung-US examination very frequently in both intensive care and inpatient services in our own clinics, and with this experience after COVID-19; we obtained very good follow-up results with this examination in these patients.

The lung ultrasound score (LUS) obtained as a result of examination of both lungs in 12 zones with Lung-US is a useful examination in the evaluation of acute respiratory distress syndrome (ARDS) and bacterial pneumonia patients. In some previous publications, it has been reported that this examination can also be used in COVID-19 patients (Vetrugno et al. 2020; Zhao et al. 2015) . However, this LUS assessment has not been evaluated in COVID-19 pneumonia. Modified LUS (mLUS) is a more specific assessment obtained by adding new parameters to the LUS score (Monastesse et al. 2017) . We considered the hypothesis that mLUS value, which is an objective parameter obtained with 12 zones Lung-US, could be more useful in terms of determining disease severity and follow-up, especially in cases with COVID-19 pneumonia, because of peripheral, bilateral and widespread lung involvement and the presence of ARDS in a significant number of cases. Therefore, in our study, it was aimed to determine the severity of pneumonia and the clinical parameters related to mLUS obtained with lung-US in patients with Covid-19 pneumonia.

In this cross sectional study, between 15 March 2020 and 30 April 2020, 92 patients with pneumonia who were diagnosed with COVID-19, which was confirmed by detecting SARS-CoV-2 RNA in nasopharyngeal swab samples in the intensive care and inpatient services of our hospital were evaluated. Before the patients were included in the study, they were evaluated by 2 separate internal diseases, chest diseases and infectious diseases specialists. In case of indecision on the diagnosis, the opinions of the doctors of the relevant branches with more experience were obtained. COVID-19 patients with mild disease,those who are in pediatric age group (<18), those with a history of pulmonary disease (e.g., asthma, chronic obstructive pulmonary disease, or restrictive pulmonary disease), severe kidney and liver dysfunction, acute myocardial infarction, heart failure, pulmonary embolism, previous heart or lung surgery, thyroid diseases, pregnancy or possibility of pregnancy, active malignancy, and those who did not accept the study were excluded from the study. The study was conducted in accordance with the Declaration of Helsinki, and was approved by the Local Ethics Committee (Adana Health Practice and Research Center, Ethics Committee, 2020). All patients were included in the study after their written consent was obtained. After exclusion criteria, 23 COVID-19 patients with mild-moderate pneumonia (Group I -13 men, 10 women and mean age 58.8 ± 5.1), 15 COVID-19 patients with severe pneumonia (Group II -7 men, 8 women and mean age 70.7 ± 9.2) and 6 critically ill COVID-19 patients (Group III -6 men, and mean age 74.3 ± 7.2) were grouped and total 44 COVID-19 patients were included in the study (Figure-1).

Before conducting Lung-US examination and other examinations, personnel and device safety were ensured in order to prevent Covid-19 contamination and spread in the light of the algorithms reported by our country's ministry of health. These safety measures were repeated before and after each Lung-US examination.

Demographic features of all patients were obtained. During Lung-US examination, all cases were monitored for electrocardiography, pulse oximetry and non-invasive blood pressure measurements. At this stage, baseline HR, systolic blood pressure (SBP), diastolic blood pressure(DBP) and SpO2 were recorded. Routine biochemistry parameters, white blood cell (WBC) count, hemogram, blood glucose level, kidney function tests, aspartate aminotransferase (AST), alanine aminotransferase (ALT), hs-CRP, D-dimer, NT-proBNP and hs-cTnI levels were measured using automated chemistry analyzer (Abbott Aeroset, MN, USA) with appropriate commercial kits (Abbott).

Patients were switched from prone position to supine position before blood gas analysis. Then, the areasurrounding radial or femoral arteries were sterilized and a 2 cc arterial blood gas sample was taken into the injector washed with 2 cc heparin. The sampling was repeated when there was a suspicion about obtaining arterial blood gas or when a venous blood gas sample was suspected in the blood gas analysis. ABL90 FLEX machine and micromode measurement method were used for blood gas analysis (Radiometer Medical ApS, Brønshøj, Denmark). As a result of the measurements, arterial partial pressure of carbon dioxide (PaCO2), arterial partial pressure of oxygen (PaO2) and PaO2 / FiO2: partial pressure of arterial oxygen / fractional inspired oxygen ratio were calculated.

We enrolled 30 patients with COVID-19, which was confirmed by detecting SARS-CoV-2 RNA in nasopharyngeal swab samples using a SARS-CoV-nucleic acid detection kit according to the manufacturer's protocol (Bioeksen İstanbul Turkey)

All patients and controls underwent pulmonary US (P-US) screening using a portable US device (Philips EPIQ 7), using a 2-5 MHz convex probe (Philips Health Care, Bothell, WA, USA). Subjects were evaluated by two well experienced radiology specialists for P-US. Specialists had more than 5 years of experience in pulmonary disease studies and at least 500 P-US procedures in a year. All USG examination time was approximately 15-20 minutes. Pulmonary US were performed using the B-mode technique, with the patient being in sittingsupine position. Examination was performed with antero-postero-lateral approach from the intercostal space. Each hemithorax was divided into 6 zones in the supine position. First, the anterior and posterior axillary lines were identified, and thorax was divided into 3 separate zones as front -middle rear zones. A single line was drawn from the nipple or 4th intercostal space perpendicular to the anterior-posterior axillary line. In this frame, a total of 6 zones were obtained by creating upper and lower zones ( Figure 2 ) (Liu et al. 2020; Monastesse et al. 2017; Soummer et al. 2012; Koh et al. 2019 ). Presence of pleural effusion was recorded. During the procedure, subjects were asked to pause breathing for a few seconds to minimize pulmonary movement occurring with respiration. In each subject, 12 valid measurements from different pulmonary zones were obtained.

In Lung-US, mLUS score was used for simple lung aeration loss assessment (Monastesse et al. 2017; Soummer et al. 2012 ). The previously mentioned 12 zones were scored between 0 and 3 with a simple grading system: 0 points for normal aeration (0 -B lines) point for mild loss of aeration (≥ B lines or or multiple small subpleural consolidations separated by a normal pleural line), 2 points for moderate loss of aeration (Multiple coalescent B lines or multiple small subpleural consolidations separated by a thickened or irregular pleural line) (Figure 3a -d) and 3 points for severe loss of aeration (consolidation or small subpleural consolidation of > 1 × 2 cm in diameter) (Figure 4a -d). A total of 12 pulmonary zone scores were obtained for both lungs, with a score between 0 and 36 The total modified LUS score of was accepted as "no aeration loss" and the modified LUS score of 6 was accepted as "complete aeration loss"

All analyzes were performed using SPSS 22.0 (SPSS for Windows 22.0, Chicago, IL, USA) statistical software package. Continuous variables in group data were indicated with mean ± standard deviation.

Categorical variables were specified with numbers and percentages. Continuous variables that showed normal distribution were compared using the ANOVA test, whereas the Kruskal-Wallis test is used to compare nonnormally distributed samples. "Chi-square (χ )" test was used to compare categorical variables. Pearson's and Spearman's correlation analysis was performed to determine parameters related to mLUS Linear regression analysis was performed for parameters which were more closely related to the parameters related to PaO 2 /FiO 2 and mLUS score in the univariate analysis. Statistical significance was accepted as p<0.05 for all comparisons.

As previously mentioned, study data were divided into 3 groups and compared. Lung-US measurements were successfully obtained from all patients included in the study. Interobserver agreement was determined as 96%.

When the demographic data were compared according to the study groups, the gender distribution was similar between the groups, but mean age of the Group I was significantly lower than Group II-III. Although the frequency of HT and DM were similar, the smoking rate in Group III was higher. It was determined that the SBP and DBP values among the clinical parameters were the lowest in Group III and were significantly lower than the other two groups (Table 1 ). It was determined that the baseline HR value increased from Group I to Group III and that Group III patients had significantly higher baseline HR values than Group I (Table 1) .

Glucose, ALT and hs-CRP levels among laboratory parameters were found to be the highest in Group III and significantly higher than Group I (Table 1) . D-dimer and NT-proBNP levels were found to be the highest in Group III and significantly higher than the other two groups (Table 1 ). It was determined that hs-cTnI level increased from Group I to Group III and was significantly higher in Group II-III than Group I (Table 1) . Other laboratory parameters were found to be similar across all groups.

When blood gas data were compared between study groups, it was determined that PaO2, PaO2 / FiO2

and SpO2 values decreased from Group I to Group III and these values were significantly different among all groups (Table 2) . It was also determined that PaCO2 value increased from Group I to Group III and was significantly different between groups (Table 2) . From Lung-US data, it was determined that mLUS and mean score values were higher in Group II and Group III patients and significantly different from Group I in both groups (Table 2) . These parameters were similar in Group II and Group III patients.

Correlation analysis was performed to determine the parameters associated with mLUS. The parameters associated with mLUS in correlation analysis are summarized in Table 3 . Linear regression analysis was performed to determine the presence of closer relationship with the parameters associated with mLUS in the correlation analysis (Table 3) . As a result of this analysis, a positive and significant relationship was found between mLUS and age and NT-proBNP levels. mLUS was found significantly and negatively associated with PaO2 / FiO2 levels ( Table 3 ). The relationship between mLUS and PaO2 / FiO2 level is shown in Figure 4 .

Our study gave important information to the literature for COVID-19 pneumonia. First of all, in patients with COVID-19 pneumonia, mLUS evaluation with Lung-US examination was performed for the first time and it was thought that this examination may be useful in evaluating the severity of the disease. It is determined that there is a close and significant relationship between PaO2 / FiO2 value -which is an important parameter for ARDS and respiratory support requirement -and mLUS. Another important finding is the determination of a positive and significant relationship between mLUS score and NT-proBNP level, which is considered important for the severity and prognosis of the disease in COVID-19 patients. Our study is the first study that evaluates the mLUS score in patients with COVID-19 pneumonia and shares the results.

Typical CT manifestations for the disease in cases with pneumonia are ground-glass opacity (GGO) or mixed GGO, consolidation, and vascular dilatation Pan et al. 2020) . For this reason, Lung-CT is widely used in the diagnosis of COVID-19 pneumonia in our country and hospital. In COVID-19 pneumonia, lesions are characterised with bilateral involvement and peripheral distribution, and lower lobes are predominantly involved Pan et al. 2020 ).

There is a general view and consensus about Lung CT and Lung-US examination which might be useful in these patients and there are growing evidence in literature data that support this opinion (Musolino et al. 2020; Mongodi et al. 2020; Vetrugno et al. 2020; Peng et al. 2020; Sofia et al. 2020; Poggiali et al. 2020) . Especially the disease's involvement of peripheral lung tissue more frequently is an important advantage for Lung-US examination. Lung-US is an easy-to-learn (≥ 25 supervised exams) and safe examination that can be performed in about 5 minutes and requires no advanced software (Rouby et al. 2020 ). X-ray and CT scans used in this disease cannot be repeated due to transport problems for critically ill patients and to limit the spread of the disease by patients infected with COVID-19. Since these scans also use ionized radiation, their repetition will cause further radiation exposure. Therefore, it is necessary to use Lung-US examination more widely.

In normal Lung-US evaluation, there is normal aeration in the lungs and A lines are observed in these patients. These A lines are parallel to the pleural line, the distance between the skin-pleural line and the pleural line-A lines are very close to each other. The main Lung-US finding for COVID-19 pneumonia are hyperechoic artifacts due to acute interstitial damage, perpendicular to the pleural line and going deep, showing vertical extension, and are called B lines (Vetrugno et al. 2020; Sofia et al. 2020; Poggiali et al. 2020; Testa et al. 2012 ).

The number, thickness and shape of B lines are very important. For example, in Lung-US evaluation, 0 -2 B lines get points while ≥ B lines get point (Monastesse et al. 2017; Koh et al. 2019 ). The number of existing B lines may increase further and multiple B lines may form a single hyperechoic image. The name of this image is specified as "white lung". White lung image in the Lung US examination is the equivalent of GGO, which is the CT finding in pneumonia patients and is considered typical for COVID-19. The next stage is lung consolidations and is specified as the hepatization of the lung parenchyma. At this stage, lung aeration also suffers a major loss. However, none of these findings are specific for COVID-19. In the studies conducted, the Lung-US examination has 80% sensitivity in terms of whether pneumonia is caused by bacterial or viral pathogens. However, available data are limited in terms of specific lung US examination in viral pneumonia patients with critical disease (Testa et al. 2012) . In our study, all participants consisted of patients who were accepted as probable COVID-19 at the first admission to the emergency department and who were diagnosed with a positive nasopharyngeal swab specimen. For this reason, we did not perform Lung-US evaluation for the diagnosis of COVID-19-induced viral pneumonia in our study.

Very recently, a letter published by Qian-Yi Peng et al. (2020) mentions their experience with lung US in 20 patients with Covid-19 pneumonia. In this very valuable article, the importance of 12 zone lung evaluation was mentioned (Peng et al. 2020; Koh et al. 2019) . Important findings for Covid-19 in these articles are as follows: i) pleural line thickening accompanied by irregularity, ii) focal, multifocal and confluent B lines, iii) multifocal small, non-translobar and translobar consolidation, iv) the presence of A lines in recovery phase and v) infrequent pleural effusion. Although these data are very valuable, there is no objective classification and no scoring system with 12 zones. However, in this letter (Peng et al. 2020 ) and previous similar articles (Vetrugno et al. 2020; Sofia et al. 2020; Poggiali et al. 2020) , only experience and case presentation information was shared and no objective algorithm and scoring system was mentioned. Another article published by Bonadia et al. a total of 14 areas (3 posterior, 2 lateral and 2 anterior for each lung) were scanned and indicates that LUS, performed in the ED by emergency physicians, is able to predict at the first evaluation the overall prognosis of COVID-19 patients, recognizing those needing ICU admission and those at higher risk of death (Bonadia et al. 2020) . In our study, we used the mLUS score as an objective parameter. As a result, we got information about the severity of lung involvement for COVID-19 pneumonia over a 36-point scoring.

COVID-19 pneumonia generally progresses in 4 stages and according to these stages, we have expert opinions and our own experiences on lung US findings (Poggiali et al. 2020) . Stage I is the onset of the disease and lung US findings are normal. Stage II is the period of mild pneumonia, these patients have multiple B lines which is simple Lung-US finding. Stage III is a severe pneumonia period, in the clinical follow-up tachypnea, severe breathlessness and SpO2 <90% is observed despite O2 support. During this period, there are diffuse or multi-focal B lines and initial subpleural consolidations in Lung-US. Stage IV is the ARDS or critical illness period and patients have PaO2 / FiO2 values between 200 and 300 and need respiratory support. In Stage IV, there are diffuse or multi-focal B lines, in addition to lung consolidation and white lung pattern in Lung-US.

However, it will be more appropriate in COVID-19 disease to obtain the Lung-US findings used in staging from all segments of both lungs. In our study, we did not include patients with Stage I COVID-19 pneumonia due to lack of Lung-US findings. We performed Lung-US evaluation on Stage II-III-IV patients. In addition, we performed the US according to this pneumonia staging with 12 zone evaluations since the COVID-19 pneumonia is disseminated within the whole lung. Thus, we obtained an objective parameter about disease severity through mLUS evaluation.

In COVID-19 patients, there are data indicating that advanced age, male gender, low lymphocyte count, increased CRP and inflammatory cytokines, increased NT-proBNP and hs-cTnI, hypotension, hypoxia, vasopressor requirement, concomitant cardiac disease and cardiovascular risk factors are associated with disease severity (Liu et al. 2020; Monastesse et al. 2017; Lyu et al. 2020; Bhatraju et al. 2020) . In our study, we showed that mLUS score increased significantly in critically ill patients with severe pneumonia. In addition, we have found that there is a very close and significant relationship between mLUS and PaO2 / FiO2, NT-proBNP level and advanced age, which are parameters proven to indicate the disease severity precisely before. Considering the previous studies on mLUS, our knowledge of the location and course of lung involvement of COVID-19 infection, and our own experience in this study, we concluded that the evaluation of mLUS would be a useful review in assessing the severity of COVID-19 disease.

There are some important limitations in our study. One of these limitations is the low number of patients in the study. Another limitation is that LUS parameters cannot be re-evaluated in cases who clinically improved or worsened due to lack of clinical follow-up. Prognosis evaluation and studies involving more patients may give more significant information. In our study, the effect of treatment applied on patients with COVID-19 pneumonia could not be evaluated. In addition, lung US examination and mLUS score were evaluated by a single physician for each patient to reduce the risk of contact and transmission of the disease, and no repeated evaluation was made. Another limitation is disease severity is already captured by respiratory parameters, age and comorbidities and this study is not designed to provide us with information about the possible prognostic role of LUS. At the time of the clinical study, we could not evaluate mLUS because patients with asymptomatic and mild pneumonia were not hospitalized in our hospital. These patients were followed up in the outpatient clinic.

Bedside Lung-US and mLUS represents an effective tool for severity of pnomonia in the intensive care unit. The mLUS value obtained with Lung-US as a result of our examination may be useful in patients with COVID-19 pneumonia and in the decision to provide respiratory support. Lung-US examination is a safe, reproducible, easily applicable, radiation-free, low-risk, easy-to-learn examination and can also reduce X-ray and CT scan frequency, therefore, the frequency of its use in COVID-19 pneumonia in diagnosis, follow-up, and disease severity determination should be increased. In conclusion, we think that Lung-US and mLUS values are useful parameters in the evaluation of the severity of pulmonary involvement in patients diagnosed with COVID-19. It may be beneficial to carry out studies that involve more patients on this subject and evaluates the regression and progression of the disease. Modified LUS score 6.5 ± 7.1 α ¥ 23.5 ± 5.9 24.7 ± 3.9 <0.001

Mean score 0.54 ± 0.58 α ¥ 1.97 ± 0.51 2.05 ± 0.33

The values were shown as mean ± standard deviation or n (%), LUS: Lung ultrasound scores, PaO 2 /FiO 2 : partial pressure of arterial oxygen/fractional inspired oxygen ratio,PaCO 2 : arterial partial pressure of carbon dioxide, PaO 2 :

arterial partial pressure of oxygen, SpO 2 : peripheral oxygen saturation, Group I= COVID-19 patients mild-moderate pneumonia Group II= COVID-19 patients with severe pneumonia Group III = COVID-19 patients with critical ill α the significant association between the Group I and Group III (p< ) ¥ = the significant association between the Group I and Group II (p<0.05) the significant association between the Group II and Group III p<0.05) hs-cTnI: high sensitive cardiac troponin I,NT-proBNP: N-terminal probrain natriuretic peptide, PaO 2 /FiO 2 : partial pressure of arterial oxygen/fractional inspired oxygen ratio in multivariate analyse.

Lung Ultrasound Findings Are Associated with Mortality and Need for Intensive Care Admission in COVID-19 Patients Evaluated in the Emergency Department

Covid-19 in Critically Ill Patients in the Seattle Region -Case Series

Predictors of Mortality for Patients with COVID-19 Pneumonia Caused by SARS-CoV-2: A Prospective Cohort Study

Relationship between PaO 2 /FiO 2 and number of regions with B-line on transthoracic lung ultrasound: a prospective, observational study

The performance of chest CT in evaluating the clinical severity of COVID-19 pneumonia: identifying critical cases based on CT characteristics

Which lessons shall we learn from the 2019 novel coronavirus outbreak?

Lung Ultrasonography for the Assessment of Perioperative Atelectasis: A Pilot Feasibility Study

Lung Ultrasound in Patients with Acute Respiratory Failure Reduces Conventional Imaging and Health Care Provider Exposure to COVID-19

Lung Ultrasound in Children with COVID-19: Preliminary Findings

Time Course of Lung Changes On Chest CT During Recovery From

Chinese Critical Care Ultrasound Study Group (CCUSG). Findings of lung ultrasonography of novel corona virus pneumonia during the 2019-2020 epidemic

Can Lung US Help Critical Care Clinicians in the Early Diagnosis of Novel Coronavirus (COVID-19) Pneumonia? Radiology

Training for Lung Ultrasound Score Measurement in Critically Ill Patients

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

Thoracic ultrasound and SARS-COVID-19: a pictorial essay

Ultrasound assessment of lung aeration loss during a successful weaning trial predicts postextubation distress

Early recognition of the 2009 pandemic influenza A (H1N1) pneumonia by chest ultrasound. Crit Care

Our Italian experience using lung ultrasound for identification, grading and serial follow-up of severity of lung involvement for management of patients with COVID-19

Prognostic value of extravascular lung water assessed with lung ultrasound score by chest sonography in patients with acute respiratory distress syndrome

hs-cTnI (ng/L) 3.05 ± 1.70 α, ¥ 9.07 ± 6.7 10.1 ± 9.74 0.019The values were shown as mean ± standard deviation or n (%), hs-CRP: High sensitive C reactive protein, hs-cTnI:high sensitive cardiac troponin I, NT-proBNP: N-terminal pro-brain natriuretic peptide Group I= COVID-19 patients mild-moderate pneumonia Group II= COVID-19 patients with severe pneumonia Group III = COVID-19 patients with critical ill α the significant association between the Group I and Group III (p< ) ¥ = the significant association between the Group I and Group II (p<0.05) the significant association between the Group II and Group III p<0.05)